# TECVAYLI (teclistamab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/teclistamab

> The FDA approved TECVAYLI (teclistamab), sponsored by JOHNSON & JOHNSON (JNJ), on Mar 2026 for with relapsed or refractory multiple myeloma.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TECVAYLI (teclistamab) |
| Codes | JNJ-64007957 |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications | [with relapsed or refractory multiple myeloma](https://sec-api.dev/indications/with-relapsed-or-refractory-multiple-myeloma), [Multiple Myeloma](https://sec-api.dev/indications/multiple-myeloma) |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### Oct 2022: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-03-11, last confirmed 2025-03-11.
- SEC Form 10-K (accession 0001801198-25-000012): "In that regard, Janssen, our cilta-cel collaboration partner, received FDA approval in October 2022 for Tecvalyi (teclistamab-cqyv), an off-the-shelf, T-cell directed, bispecific antibody targeting both BCMA and CD3." https://www.sec.gov/Archives/edgar/data/1801198/000180119825000012/legn-20241231.htm

### October 13, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05572515 (A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05572515

### Mar 2026: FDA approval

- Status: completed, approved. Date confidence: month. Indication: with relapsed or refractory multiple myeloma.
- First seen 2026-05-11, last confirmed 2026-05-11.
- Press release filed with the SEC (EX-99) (accession 0001159036-26-000067): "•In March 2026, Janssen announced the FDA approved TECVAYLI® (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy." https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/ex991q120268-k.htm

## Same indication

- [Anitocabtagene autoleucel](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) (GILD)
- [Arlocabtagene autoleucel](https://sec-api.dev/pdufa/arlocabtagene-autoleucel) (BMY)
- [BB2121](https://sec-api.dev/pdufa/bb2121) (BMY)
- [Belantamab mafodotin](https://sec-api.dev/pdufa/belantamab-mafodotin) (GSK)
- [Cemsidomide](https://sec-api.dev/pdufa/cemsidomide) (CCCC)
- [Cilta-cel](https://sec-api.dev/pdufa/cilta-cel) (JNJ)
- [CARVYKTI (ciltacabtagene autoleucel)](https://sec-api.dev/pdufa/ciltacabtagene-autoleucel) (JNJ)
- [DARZALEX (daratumumab)](https://sec-api.dev/pdufa/daratumumab) (JNJ)
- [Empliciti (elotuzumab)](https://sec-api.dev/pdufa/elotuzumab) (BMY)
- [Elrexfio (elranatamab)](https://sec-api.dev/pdufa/elranatamab) (PFE)
- [Etentamig](https://sec-api.dev/pdufa/etentamig) (ABBV)
- [Zenbexus (iberdomide hydrochloride)](https://sec-api.dev/pdufa/iberdomide) (BMY)
- [ABECMA (idecabtagene vicleucel)](https://sec-api.dev/pdufa/idecabtagene-vicleucel) (BMY)
- [Igi, 10%](https://sec-api.dev/pdufa/igi-10) (TAK)
- [JNJ-79635322](https://sec-api.dev/pdufa/jnj-79635322) (JNJ)
- [Revlimid® (lenalidomide)](https://sec-api.dev/pdufa/lenalidomide) (JNJ)
- [PHE885](https://sec-api.dev/pdufa/phe885) (NVS)
- [Pomalyst (pomalidomide)](https://sec-api.dev/pdufa/pomalidomide) (BMY)
- [Ramantamig](https://sec-api.dev/pdufa/ramantamig) (JNJ)
- [Talquetamab](https://sec-api.dev/pdufa/talquetamab) (JNJ)
- [Venclexta (venetoclax)](https://sec-api.dev/pdufa/venetoclax) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/teclistamab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TECVAYLI (teclistamab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/teclistamab

```bibtex
@misc{secapidev_pdufa_teclistamab_20261116,
  title        = {TECVAYLI (teclistamab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/teclistamab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_teclistamab_20261116","title":"TECVAYLI (teclistamab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/teclistamab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
